Synthesis of 5-arylidene-2-aryl-3-(phenothiazino/benzotriazoloacetamidyl)-1,3-thiazolidine-4-ones as antiinflammatory, anticonvulsant, analgesic and antimicrobial agents

Seema Mishra, S K Srivastava* & S D Srivastava, Synthetic Organic Chemistry Laboratory, Department of Chemistry, Dr H S Gour University, Sagar 470 003(MP), India


Received 21 August 1996; accepted (revised) 2 May 1997

Condensation of N¹⁰ (acetohydrazido) phenothiazine/benzotriazole 5, 6 with various carbonyls give arylidene acetohydrazido phenothiazines/benzotriazoles 7, 8 which on cycloaddition with mercapto acetic acid yield the corresponding 4-thiazolidinones 9a-e and 10a-e. Treatment of these 4-thiazolidinones with various carbonyl compounds afford 5-arylidene-2-aryl-3-(phenothiazino/benzotriazolo acetamidyl)-1,3-thiazolidine-4-ones 11a-I and 12a-I respectively.

Phenothiazine and benzotriazole derivatives possess potent biological activities^{1,2} including anthelmintic and antiinflammatory activities. 4-Thiazolidinones are well known for versatile pharmacological activities³⁻⁵ such as hypnotic, anaesthetic, antifungal, analgesic, antiviral, antithyroid, anticonvulsant, CNS stimulant, etc.

The present paper reports the synthesis of 4-thiazolidinones by appropriate methods. All the compounds have been screened for their antiinflammatory activity against the carrageenan induced rat paw oedema in albino rats, anticonvulsant activity against pentylenetetrazole induced convulsions in mice, analgesic activity by the Eddy and Leimbach method using Technoheated plate analgesic apparatus and antimicrobial activity by the agar plate diffusion technique.

Phenothiazine/benzotriazole on N-esterification with ethyl chloroacetate in acetone/chloroform gave ethyl ethanoate/phenothiazine/benzotriazole **3**, **4** which on ammonolysis with hydrazine hydrate in



Scheme I

ethanol/methanol yielded acetohydrazido phenothiazine/benzotriazole 5, 6. Compounds 5, 6 on condensation with various carbonyls afforded arylidene acetohydrazido phenothiazine/benzotriazole 7, 8 which on cyclocondensation with thioglycolic àcid in presence of anhyd. ZnCl₂ furnished 2-aryl-3- (phenothiazino/benzotriazolo acetamidyl)-1,3-thiazolidene-4-ones 9, 10. Compounds 9, 10 on reaction with various carbonyls using sodium ethoxide in dioxane/benzene yielded 5-arylidene-2-aryl-3-(phenothiazino/benzotriazolo acetamidyl)-1,3-thiazolidine-4-ones 11, 12 (Scheme I).

The structures of these compounds were established on the basis of their elemental analysis, IR, PMR and mass spectra (Table I).

Biological activities

Antiinflammatory activity

Carrageenan induced rat paw oedema method was employed for evaluating the antiinflammatory activity of **11 a-l** and **12 a-l** at a dose of 4 mg/kg b.w. in

Note

NOTES

Compd	R_1	R ₂	R ₃	R4	Yield	m.p.	Mol. formula	Found(%) (Calcd)		
					(%)	(°C)		С		N
7b	Н	CH=CH.C ₆ H ₅	-	-	57	138	C ₂₃ H ₁₉ N ₃ OS	71.6 (71.6)	H 4.8 (4.9)	N 10.8 (10.9)
c	Н	p-Cl.C ₆ H ₄	-		61	93	C ₂₁ H ₁₆ N ₃ OSCI	64.0 (64.0)	3.9 (4.0)	10.5 (10.6)
d	Н	o-Cl.C ₆ H ₄	-		63	91	C ₂₁ H ₁₆ N ₃ OSCI	64.0 (64.0)	4.0 (4.0)	10.5 (10.6)
e	C ₆ H ₅	C6H5	-	1.	66	178	C27H21N3OS	74.4 (74.4)	4.7 (4.8)	9,6 (9.6)
8b	Н	CH=CH.C ₆ H ₅	-	-	54	82	C17H15N5O	66.7 (66.8)	4.9 (4.9)	22.9 (22.9)
¢	Н	p-Cl.C6H5	-	-	55	79	C ₁₅ H ₁₂ N ₅ OCl	57.3 (57.4)	3.7 (3.8)	22.3 (22.3)
d	Н	o-Cl.C ₆ H ₄	•	•	55	77	C15H12N5OCI	57.3 (57.4)	3.7 (3.8)	22.3 (22.3)
e	C ₆ H ₅	C ₆ H ₅	-	-	56	67	C ₂₁ H ₁₇ N ₅ O	70.9 (70.9)	4.7 (4.7)	19.6 (19.7)
9b	Н	CH=CH.C ₆ H ₅	-	-	64	142	$C_{25}H_{21}N_3O_2S_2$	65.2 (65.3)	4.3 (4.5)	9.1 (9.1)
c	Н	p-Cl.C ₆ H ₄	-	-	47	89	C ₂₃ H ₁₈ N ₃ O ₂ S ₂ Cl	59.0 (59.0)	3.7 (3.8)	8.8 (8.9)
d	Н	o-Cl.C ₆ H ₄	-	-	50	87	C ₂₃ H ₁₈ N ₃ O ₂ S ₂ Cl	59.0 (59.0)	3.7 (3.8)	8.9 (8.9)
e	C ₆ H ₅	C ₆ H ₅	-	-	47	173	$C_{29}H_{23}N_3O_2S_2$	68.1 (68.3)	4.4 (4.5)	8.1 (8.2)
10b	Н	CH=CH.C ₆ H ₅	-	. য	71	90	C ₁₉ H ₁₇ N ₅ O ₂ S	60.0 (60.1)	4.2 (4.4)	18.4 (18.4)
с	Η	p-Cl.C ₆ H ₄	-	-	65	74	C17H14N5O2SCI	52.5 (52.6)	3.5 (3.6)	18.0 (18.0)
d	Н	o-Cl.C ₆ H ₄	-	-	69	72	C ₁₇ H ₁₄ N ₅ O ₂ SCl	52.6 (52.6)	3.5 (3.6)	18.0 (18.0)
e	C ₆ H ₅	C6H5	-	-	60	67	C ₂₃ H ₁₉ N ₅ O ₂ S	64.3 (64.3)	4.4 (4.4)	16.3 (16.3)
l1b	Η	C4H3O	Н	p-Cl.C ₆ H ₄	61	83	C ₂₈ H ₂₀ N ₃ O ₃ S ₂ Cl	61.5 (61.5)	3.6 (3.6)	7.6 (7.6)
2	Н	C4H3O	Н	p-N(CH3)2.C6H4	58	103	C ₃₀ H ₂₆ N ₄ O ₃ S ₂	64.8 (64.9)	4.6 (4.6)	10.0 (10.1)
ł	Н	C4H3O	C ₆ H ₅	C ₆ H ₅	51	121	$C_{34}H_{25}N_3O_2S_2$	69.4 (69.5)	4.2 (4.2)	7.1 (7.1)
2	Н	CH=CH.C6H5	Н	<i>p</i> -Cl.C ₆ H ₄	48	87	C ₃₂ H ₂₄ N ₃ O ₂ S ₂ Cl	66.0 (66.0)	4.1 (4.1)	7.1 (7.1)
Ĩ	Н	CH=CH.C6H5	Н	<i>p</i> -N(CH ₃) ₂ C ₆ H ₄	51	154	C34H30N4O2S2	69.0 (69.1)	5.0 (5.0)	9.2 (9.4)
g	Н	CH=CH.C ₆ H ₅	Н	C ₆ H ₅	57	171	C38H29N3O2S2	73.0 (73.1)	4.5 (4.6)	6.7 (6.7)
1	Н	p-Cl.C ₆ H ₄	Н	o-Cl.C6H4	51	74	C ₃₀ H ₂₁ N ₃ O ₂ S ₂ Cl ₂	61.0 (61.0)	3.5 (3.5)	(0.7) 7.0 (7.1)
	Н	<i>p</i> -Cl.C ₆ H ₄	Н	<i>p</i> -N(CH ₃) ₂ .C ₆ H ₄	56	111	C ₃₂ H ₂₇ N ₄ O ₂ S ₂ Cl	64.1 (64.1)	4.4 (4.5)	9.1 (9.3)

Contd...

Compd	R ₁	R ₂	R ₃	R4	Yield (%)	m.p. (°C)	Mol. formula	Found(%) (Calcd)		
								С	Н	Ν
j	Н	p-Cl.C6H4	C ₆ H ₅	C6H5	55	116	C36H26N3O2S2Cl	68.3 (68.4)	4.1 (4.1)	6.4 (6.6)
k	H	o-Cl.C ₆ H ₄	C ₆ H ₅	C ₆ H ₅	53	118	C36H26N3O2S2Cl	68.3 (68.4)	4.1 (4.1)	6.4 (6.6)
I	C ₆ H ₅	C ₆ H ₅	Н	<i>p</i> -N(CH ₃) ₂ C ₆ H ₄	50	161	$C_{38}H_{32}N_4O_2S_2$	71.1 (71.2)	5.0 (5.0)	8.7 (8.7)
12b	Н	C4H3O	Н	<i>p</i> -Cl.C ₆ H ₄	55	32	C22H16N5O3SC1	56.6 (56.7)	3.3 (3.4)	15.0 (15.0)
c	Н	C4H3O	Н	<i>p</i> -N(CH ₃) ₂ C ₆ H ₄	50	53	C ₂₄ H ₂₂ N ₆ O ₃ S	60.7 (60.7)	4.6 (4.6)	17.7 (17.7)
d	Н	C4H3O	C ₆ H ₅	C6H5	49	66	C ₂₈ H ₂₁ N ₅ O ₃ S	66.2 (66.2)	4.0 (4.1)	13.7 (13.8)
e	Н	-CH=CH.C6H5	Н	p-Cl.C ₆ H ₄	53	44	C ₂₆ H ₂₀ N ₅ O ₂ SCI	62.1 (62.2)	3.9 (3.9)	13.9 (13.9)
f	Н	-CH=CH.C6H5	Н	<i>p</i> -N(CH ₃) ₂ C ₆ H ₄	58	70	$C_{28}H_{26}N_6O_2S$	65.8 (65.8)	5.0 (5.0)	16.2 (16.4)
g	Н	-CH=CH.C6H5	C ₆ H ₅	C ₆ H ₅	55	85	C ₃₂ H ₂₅ N ₅ O ₂ S	70.8 (70.9)	4.5 (4.6)	12.8 (12.8)
h	Н	<i>p</i> -Cl.C ₆ H ₄	Н	-Cl.C6H4	48	29	C24H17N5O2SCl2	56.4 (56.4)	3.3 (3.3)	13.6 (13.7)
i	Н	p-Cl.C ₆ H ₄	Н	p-N(CH3)2C6H4	51	64	C ₂₆ H ₂₃ N ₆ O ₂ SC1	60.1 (60.1)	4.4 (4.4)	16.1 (16.2)
j	Н	p-Cl.C ₆ H ₄	C ₆ H ₅	C ₆ H ₅	55	68	C ₃₀ H ₂₂ N ₅ O ₂ SC1	65.2 (65.2)	3.9 (3.9)	12.4 (12.6)
k	Н	o-Cl.C ₆ H ₄	C ₆ H ₅	C ₆ H ₅	56	67	C ₃₀ H ₂₂ N ₅ O ₂ SCl	65.2 (65.2)	3.9 (3.9)	12.4 (12.6)
1	C ₆ H ₅	C6H5	Н	<i>p</i> -N(CH ₃) ₂ C ₆ H ₄	63	74	C ₃₂ H ₂₈ N ₆ O ₂ S	68.5 (68.5)	5.0 (5.0)	14.9 (15.0)

able 1-Characterization data of compounds 7-12 (Contd..)

albino rats (weighing 80-115 g). The rat paw oedema was produced by the method of Winter *et al.*⁶ The percentage inhibition of inflammation was calculated by applying Newbould formula⁷. In this test the most active compounds were **11c**, **f**, **g**, **1** (58%, 72%, 52% and 75%) and **12a,c,d,f,g,1** (58%, 66%, 50%, 83%, 80% and 75%) inhibition respectively and their activity was compared with phenylbutazone (94% inhibition) at a dose of 4 mg/kg b.w.

Anticonvulsant activity

The compounds **11a-l** and **12a-l** were screened for their anticonvulsant activity against the pentylene tetrazole induced convulsion in albino rats of either sex (weighing 80-115 g) by the method given in literature^{8.9}. The compounds were suspended in 5% aq. gum acacia to give a concentration of 25% (w/v). The test compounds were injected i.p. at a dose of 50 mg/kg b.w. 4 hr after the administration of compounds. The rats were injected with pentylenetetrazole (50 mg/kg). Compounds **11f,g,l** and **12f,g** provided 80, 70, 60, 50 and 40% protection respectively against the pentylenetetrazole induced convulsions in rats compared to 100% activity of phenobarbitone (a reference drug) at 50 mg/kg b.w.).

Analgesic activity

The synthesised compounds **11a-l** and **12a-l** were tested for their analgesic activity in albino rats (weighing 80-115 g) by Eddy and Leimbach method¹⁰ at an oral dose 25 mg/kg b.w. Acetyl salicylic acid was employed as a standard drug. The

Antimicrobial activity

The compounds 9-12 were screened for their antibacterial activity against *Bacillus subtilis*, *Salmonella typhimurium* and *Escherichia coli* and antifungal activity against *Candida albicans*, *Fusarium heterosporium* and *Aspergillus niger* by filter paper disc technique^{11,12} at two concentrations (25 and 50 µg/ml). Standard antibacterial streptomycin and antifungal griseofulvin were also screened under similar conditions for comparison. The compounds **11f,l** and **12c,f,g,l** had good antibacterial activity while compounds **11c,f,l** and **12a,f,l** were found to have pronounced antifungal activity.

Experimental Section

Melting points were taken in an open capillary tube and are uncorrected. IR spectra (KBr) were recorded on an Acculab-10 spectrophotometer ($\max_{in cm-1}$) and PMR spectra in CDCl₃ on 90 MHz on Varian CFT-20 instrument using TMS as an internal standard (chemical shifts in δ , ppm).

Ethyl ethanoate phenothiazine 3/benzotriazole 4. Ethyl chloroacetate (0.05mole) was added to a solution of phenothiazine/benzotriazole (0.05 mole) and anhyd. K₂CO₃ (3 g) in ethanol and the reaction mixture was refluxed for 15 hr. Solvent was removed in vacuo and the residue was crystallised from chloroform to give 3, yield 82%, m.p. 203° (Found: C,67.3; H,5.2; N,4.8. C₁₆H₁₅O₂NS requires C,67.4; H,5.3; N,4.9%); IR: 3020, 1580, 925, 755, 740, 680 and 650 (phenothiazine nucleus), 1720(>C=O ester); PMR: $1.20(t, 3H, J = 7Hz, -COOCH_2CH_3), 4.10(q, 2H, J =$ 7Hz: COOCH2CH3), 3.60(s, 2H, N-CH2), 7.20-7.90 (m, 8H, Ar-H); MS: 285(M⁺). 4: Yield 83%, m.p. 40° (Found: C,58.5; H,5.3; N,20.4. C₁₀H₁₁O₂H₃ requires C,58.5; H,5.4; N,20.5%); IR: 3020, 1620, 1485, 865, 725 (benzotriazole nucleus), 1715(>C=O); PMR: 1.20 (t, 3H, J = 7Hz, COOCH₂CH₃), 3.60(s, 2H, N-CH₂), 4.10(q, 2H, J = 7Hz, COOCH₂CH₃), 7.30-7.80(m, 4H, Ar-H); MS: 205(M⁺).

Acetohydrazido phenothiazine 5/benzotriazole 6. A mixture of 3/4 (0.028 mol) and hydrazine hydrate (100%; 0.028 mole) was Orefluxed on a steam bath for 5 hr, cooled and filtered to get compounds 5/6. 5: Yield 76%, m.p. 170° (Found: C,61.9; H, 4.6; N,15.3. 829

C₁₄H₁₃ON₃S requires C,62.0; H,4.8; N,15.5%); IR:3350-3200(- NHNH₂), 1660(>C=O, amido); PMR; 2.50(s, 2H, -NH₂), 3.65 (s, 2H, N-CH₂), 7.10-7.80(m, 8H, Ar-H), 8.20 (s, 1H, CONH); MS: 271(M⁺). 6:Yield 60%, m.p. 85° (Found: C,50.2; H,4.7; N,36.5. C₈H₉ON₅ requires C,50.3; H,4.7; N,36.6%); IR: 3350(NHNH₂), 1660(>C=O, amido); PMR: 2.50(s, 2H, NH₂), 3.65 (s, 2H, N-CH₂), 7.90 (s, 1H, CONH), 7.40-7.70 (m, 4H, Ar-H); MS: 191(M⁺).

Arylidene acetohydrazido phenothiazine 7a/benzotriazole 8a. A mixture of 5a/6a (0.0036 mole), furfuraldehyde (0.0036 mole) and 2-3 drops of gl. acetic acid in ethanol (26 mL) was refluxed on a steam bath for 5 hr. The solvent was removed under reduced pressure to yield a product 7a/8a respectively, 7a: Yield 82%, m.p. 143° (Found: C,65.1; H,4.2; N,12.0%. C₁₉H₁₅N₃O₂S requires C,65.3; H.4.2; N.12.0%); IR: 3300-3290(-NH-), 1670(>C=O), 1620(-CH=N-); PMR: 4.40(s, 1H, -N=CH-), 3.70(s, 2H, N-CH₂), 8.00 (s, 1H, -CONH-). and 7.00-7.90 (m, 11H, Ar-H); MS:349(M⁺). 8a: Yield 58%, m.p.76° (Found: C,57.9; H,4.0; N,26.0%. C13H11N5O2 requires C,57.9; H,4.0; N,26.0%); IR: 3300-3280 (-NH-), 1680(>C=O), 1620(-CH=N-); PMR: 4.50(s, 1H, -N=CH-), 3.70 (s, 2H, N-CH₂), 8.10 (s, 1H, -CONH) and 7.30-7.90(m, 7H, Ar-H); MS: 269(M⁺). Other compounds 7b-e and 8b-e were prepared from 5 and 6 similarly using different carbonyl compounds. Characterization data are presented in Table I.

2 Aryl-3-[phenothiazino 9a/benzotriazolo 10a acetamidyl]-1.3- thiazolidine-4-ones. To a stirred solution of 7a/8a (0.0025 mole) in dioxane containing a pinch of anhyd. ZnCl₂, mercaptoacetic acid (0.0025 mole) was added and the mixture was refluxed on a steam bath for about 12 hr. Solvent was distilled off at reduced pressure and recrystallized from methanol/chloroform to yield compounds 9a and 10a respectively. 9a: Yield 60%, m.p. 148° (Found: C,59.4; H,4.0; N,9.8%. C21H17N3O3S2 requires C,59.5; H,4.0; N,9.9%); IR: 3240 (-NH-), 1715(>C=O, cyclic), 1670(>C=O, amidyl); PMR: 3.20(s, 1H, CHN-), 3.40(s, 2H, CH₂-S-), 3.70 (s, 2H, NCH₂), 8.60 (s, 1H, CONH) and 7.10-7.90 (m, 11H, Ar-H); MS: 423(M⁺). 10a: Yield 65%, m.p.78° (Found: C,52.4; H,3.7; N, 20.3%. C15H13N5O3S requires C,52.4; H,3.7; N,20.4%); IR: 3240-3220(-NH-), 1720(>C=O, cyclic), 1670(>C=O, amidyl); PMR: 3.20(s, 1H, -CHN-), 3.40(s, 2H, CH₂S), 3.70

100

(s, 2H, NCH₂), 8.50(s, 1H, -CONH-) and 7.40-7.90 (m, 7H, Ar-H); MS: 343(M⁺). Other compounds **9b-e** and **10b-e** were synthesised in the similar way using **7b-e** and **8b-e** respectively. Characterisation data are presented in Table I.

5-arylidene-2-aryl-3-[phenothiazino 11a/benzotriazolo 12a acetamidyl]-1,3-thiazolidine-4ones. Equimolar solution of 9a/10a (0.0015 mole) and cinnamaldehyde in dioxane in the presence of C2H5ONa was refluxed for 3 hr on a steam bath and the solvent was removed under reduced pressure. The products so obtained were recrystallised from ethanol to give 11a and 12a respectively. 11a: Yield 52%, m.p.76° (Found: C, 67.0; H, 4.1; N, 7.7%, C₃₀H₂₃N₃O₃S₂ requires C, 67.0; H, 4.2; N, 7.8%); IR: 3340(-NH-), 1715(>C=O, cyclic), 1650(>CO; amidyl), 1630(>C=CHAr); PMR: 3.20 (s, 1H, -CHN-), 3.60(s, 2H, -NCH₂), 5.20 (s, 1H, >C=CHAr), 8.70 (s, 1H, -CONH), 7.10-8.00(m, 16H, Ar-H); MS: 537((M⁺). 12a: Yield 57%, m.p. 47°(Found: C,63.0; H, 4.1; N,15.2%. C24H19N5O3S requires C,63.0; H, 4.1; N, 15.3%); IR: 3330(-NH-), 1720(>C=O cyclic), 1650(>C=O, amidyl), 1620(>C=CHAr); PMR: 3,30(s, 1H, CHN), 3.60 (s, 2H, NHCH₂), 5.20(s, 1H, >C=CHAr), 8.70 (s, 1H, CONH), 7.10-8.00(m, 12H, Ar-H); MS: 457(M⁺). Other compounds 11b-l and 12b-l were synthesised similarly from 9b-e and 10be respectively and carbonyl compounds. Characterization data are presented in Table I.

Acknowledgement

The authors are thankful to RSIC, CDRI Lucknow for providing spectral and analytical data of the compounds. We are also thankful to the Heads, Pharmacy and Botany Deptt. of Dr H S Gour University, Sagar for biological screenings.

References

- Upadhyay R K, Srivastava S D & Srivastava S K, J Indian Council Chem, IX2, 1993, 36.
- Purohit M & Srivastava S K, Indian J Pharm Sci, 53, 1991, 12.
- Shahsafi M A, Talsadat M & Parekh H, Indian J Chem, 26B, 1987, 803.
- Desai N C, Shukla H K & Thaker K A, J Indian Chem Soc, LXI, 1984, 239.
- Hogale M B, Uthale A C & Nikam B P, Indian J Chem, 30B, 1991, 717.
- Winter C A, Risley E A & Nuss G W, Proc Soc Exptl Biol, 3, 1962, 544.
- 7. Newbould B B, Brit J Pharmacol, 21, 1963, 157.
- 8. Goodman L S, J Pharmacol, 106, 1953, 303.
- Pandey B R, Parmar S S, Kumar S & Brumleve, *Pharmacology*, 16, 1978, 394.
- Eddy N B & Leimbach D J, *Pharm Expl Thera*, 107, 1953, 385.
- Bauer A W, Kirby W W M, Sherries J L & Turk M, Am J Cli Path, 45, 1966, 493.
- Vincent J G & Vincent H W, Proc Soc Exptl Biol Med, 55, 1955, 112.